{"id":"ace-011","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Thrombotic events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ACE-011 binds to and sequesters activin ligands, preventing their interaction with activin receptors. By blocking activin signaling, which normally suppresses erythroid differentiation, the drug promotes red blood cell production. This mechanism is intended to increase hemoglobin levels in patients with anemia, particularly those with myelodysplastic syndromes or chronic kidney disease.","oneSentence":"ACE-011 is an activin receptor type IIA ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:18:38.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myelodysplastic syndromes with anemia"},{"name":"Chronic kidney disease-related anemia"}]},"trialDetails":[{"nctId":"NCT07218029","phase":"PHASE3","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-12","conditions":"Pulmonary Arterial Hypertension","enrollment":815},{"nctId":"NCT06814145","phase":"PHASE2","title":"Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-16","conditions":"Hypertension, Pulmonary","enrollment":130},{"nctId":"NCT07498803","phase":"PHASE2","title":"Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Philipps University Marburg","startDate":"2026-09-01","conditions":"Congenital Heart Disease (CHD), Eisenmenger Syndrome, PAH","enrollment":40},{"nctId":"NCT07487441","phase":"","title":"Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.","status":"NOT_YET_RECRUITING","sponsor":"Franz Rischard, DO","startDate":"2026-03-15","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension","enrollment":30},{"nctId":"NCT05587712","phase":"PHASE2","title":"Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-01-19","conditions":"Pulmonary Arterial Hypertension","enrollment":42},{"nctId":"NCT07140484","phase":"PHASE4","title":"Sotatercept in Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2025-10-06","conditions":"Pulmonary Artery Hypertension","enrollment":27},{"nctId":"NCT05818137","phase":"PHASE3","title":"A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-10","conditions":"Pulmonary Arterial Hypertension","enrollment":46},{"nctId":"NCT04896008","phase":"PHASE3","title":"A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2021-12-01","conditions":"Pulmonary Arterial Hypertension","enrollment":173},{"nctId":"NCT04945460","phase":"PHASE2","title":"A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2021-12-29","conditions":"Hypertension, Pulmonary","enrollment":164},{"nctId":"NCT06351345","phase":"PHASE2","title":"129 Xenon Imaging in Patients Treated With Sotatercept","status":"RECRUITING","sponsor":"Bastiaan Driehuys","startDate":"2025-10-27","conditions":"Pulmonary Hypertension, Pulmonary Arterial Hypertension","enrollment":14},{"nctId":"NCT07357974","phase":"PHASE1, PHASE2","title":"Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Brest","startDate":"2026-01-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":15},{"nctId":"NCT07356778","phase":"PHASE4","title":"A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy","status":"RECRUITING","sponsor":"Kazuya Hosokawa","startDate":"2025-10-07","conditions":"Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease","enrollment":36},{"nctId":"NCT06409026","phase":"PHASE4","title":"Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-07-05","conditions":"Pulmonary Arterial Hypertension","enrollment":30},{"nctId":"NCT01562405","phase":"PHASE1","title":"Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2012-05","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT06930664","phase":"PHASE1","title":"A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-16","conditions":"Healthy","enrollment":146},{"nctId":"NCT07266519","phase":"PHASE2","title":"SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Philipps University Marburg","startDate":"2026-07-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":25},{"nctId":"NCT06664801","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-14","conditions":"Pulmonary Arterial Hypertension","enrollment":164},{"nctId":"NCT06925750","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-12","conditions":"Pulmonary Arterial Hypertension","enrollment":130},{"nctId":"NCT06658522","phase":"PHASE4","title":"Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2025-05-14","conditions":"Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT04811092","phase":"PHASE3","title":"Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2022-03-18","conditions":"Pulmonary Arterial Hypertension","enrollment":321},{"nctId":"NCT06941441","phase":"PHASE3","title":"PAH Exercise Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-04-15","conditions":"Pulmonary Arterial Hypertension (PAH), Exercise Therapy","enrollment":10},{"nctId":"NCT06751082","phase":"","title":"Real World Observational Study of Sotatercept for Pulmonary Hypertension","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2025-01-20","conditions":"Pulmonary Hypertension","enrollment":120},{"nctId":"NCT06843460","phase":"PHASE1","title":"A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-22","conditions":"Healthy","enrollment":24},{"nctId":"NCT00747123","phase":"PHASE2","title":"A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2008-09-01","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT04576988","phase":"PHASE3","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2021-01-25","conditions":"Pulmonary Arterial Hypertension","enrollment":324},{"nctId":"NCT01284348","phase":"PHASE2","title":"To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-25","conditions":"Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung","enrollment":26},{"nctId":"NCT03738150","phase":"PHASE2","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2019-04-19","conditions":"Pulmonary Arterial Hypertension","enrollment":21},{"nctId":"NCT01999582","phase":"PHASE2","title":"A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-11-30","conditions":"Anemia, Kidney Failure, Chronic","enrollment":50},{"nctId":"NCT01146574","phase":"PHASE2","title":"A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.","status":"COMPLETED","sponsor":"Celgene","startDate":"2010-06-30","conditions":"Anemia","enrollment":50},{"nctId":"NCT01190644","phase":"PHASE2","title":"Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-01","conditions":"Solid Tumors","enrollment":5},{"nctId":"NCT01712308","phase":"PHASE2","title":"Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-21","conditions":"Anemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis","enrollment":56},{"nctId":"NCT00931606","phase":"PHASE2","title":"Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-06-01","conditions":"Chemotherapy Induced Anemia","enrollment":30},{"nctId":"NCT01571635","phase":"PHASE2","title":"Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.","status":"TERMINATED","sponsor":"Celgene","startDate":"2012-10-10","conditions":"Beta Thalassemia Major, Beta Thalassemia Intermedia","enrollment":46},{"nctId":"NCT03496207","phase":"PHASE2","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2018-06-13","conditions":"Pulmonary Arterial Hypertension","enrollment":106},{"nctId":"NCT01464164","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2012-01","conditions":"Diamond Blackfan Anemia","enrollment":19},{"nctId":"NCT01736683","phase":"PHASE2","title":"Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-28","conditions":"Anemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia","enrollment":74},{"nctId":"NCT00709540","phase":"PHASE1","title":"A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2008-01","conditions":"Osteoporosis","enrollment":40},{"nctId":"NCT03724227","phase":"","title":"Expanded Access for ACE-011","status":"NO_LONGER_AVAILABLE","sponsor":"Celgene","startDate":"","conditions":"Myelodysplastic Syndrome","enrollment":""},{"nctId":"NCT02230917","phase":"PHASE2","title":"A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"Rebecca Silbermann","startDate":"2014-10","conditions":"Multiple Myeloma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sotatercept","hActRIIA-IgG1"],"phase":"phase_2","status":"active","brandName":"ACE-011","genericName":"ACE-011","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ACE-011 is an activin receptor type IIA ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels. Used for Myelodysplastic syndromes with anemia, Chronic kidney disease-related anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}